XSTO
CAMX
Market cap3.84bUSD
Oct 07, Last price
643.00SEK
1D
0.94%
1Q
16.91%
Jan 2017
504.14%
IPO
948.23%
Name
Camurus AB
Chart & performance
P/E
52.02
P/S
16.89
EPS
12.36
Div yield, %
—
Shrs. gr., 5y
2.64%
Rev. gr., 5y
46.47%
Revenues
2.27b
+21.30%
Net income
736m
+71.70%
CFO
869m
+124.05%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.
Related entities
Subsidiaries
Camurus Development AB
Key people
Per Wallstroem
Independent Chairman of the Board · since 2015
Behshad Sheldon
President · since 2024
Jon Alonso
Chief Financial Officer · since 2022
Anders Vadsholt
Chief Financial Officer · since 2025
Markus Johnsson
Senior Vice President R and D · since 2021
Torsten Malmstroem
Chief Technical Officer · since 2019
Annette Mattsson
Vice President - Regulatory Affairs · since 2017
Agneta Svedberg
Vice President - Clinical Development · since 2023
Fredrik Joabsson
Chief Business Development Officer · since 2021
Bo Tarras-Wahlberg
Vice President, General Counsel · since 2024
Richard Jameson
Chief Commercial Officer · since 2016
Maria Lundqvist
Global Head of Human Resources · since 2021
Alberto Pedroncelli
Chief Medical Officer · since 2023
Director · since 2022
Fredrik Tiberg
Chief Executive Officer, Chief Scientific Officer, Director · since 2024
Independent Director · since 2025
Independent Director · since 2020
Erika Johnsson
Independent Director · since 2023
Jakob Lindberg
Independent Director · since 2021
Robert Mcquade
Independent Director · since 2025
Headquarters & legal address
Rydbergs torg 4
Lund, M 224 84
SE
Lund, M 224 84
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||